Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92589Research ArticlePrimenenie botulinicheskogo toksina tipa A u bol'nykh s idiopaticheskoy detruzornoy giperaktivnost'yuMazoE. B-KrivoborodovG. G-Vasil'evA. V-15042008104111328122021Copyright © 2008, Consilium Medicum2008[Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population - based prevalence study. BJU Int 2001; 87: 760–6.][Schurch B, Stohrer M, Kramer G et al. Botulinum toxin - A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholenergic drugs. J Urol 2000; 164: 692–7.][Abrams P, Cardozo L, Fall M et al. The Standardisation of Terminology of lower urinary tract function: Report from the Standardisation Sub - committee of the International Continence Society. Neurourol Urodynam 2002; 21: 167–78.][Brading A.F. A myogenic basis for the overactive bladder. Urology 1997; 50 (suppl. 6A): 55.][Boone T.B., Payne C.K., Gormlrey. Diagnosis and treatment of urge incontinence. AUA News 2000; 5 (6): 9–10.][Appell R.A., Diokho A, Antoci J et al. One - year, prospective, open - label trial of controlled - release oxybutinin for overactive bladder in a community - based population [abstract]. Neurourol Urodyn 2000; 19: 526.][Frenkl T.L., Rackley R.R. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin N Am 2005; 32: 89–99.][Radziszewski P, Dobronski A, Borkowski A. Treatment of the non - neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A – a pilot study [abstract]. Neurourol Urodyn 2001; 20: 410–12.]